Is Entero Healthcar overvalued or undervalued?

As of 14 November 2025, Entero Healthcar's valuation grade has moved from attractive to very attractive, indicating a significant positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 44.13, an EV to EBITDA of 23.43, and a PEG ratio of 0.31, which suggests strong growth potential relative to its price. In comparison to its peers, Entero Healthcar's PE ratio is notably higher than TCS at 22.34 and Infosys at 22.19, both of which are categorized as attractive and fair, respectively. Additionally, while Wipro is also rated very attractive with a PE of 18.99, Entero's growth prospects appear more favorable given its lower PEG ratio. Despite recent underperformance relative to the Sensex, with a year-to-date return of -20.6% compared to the Sensex's 8.22%, the valuation metrics suggest that Entero Healthcar presents a compelling investment opportunity.